OIPE IAP81 DEC 20 2006 PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	K. Ballard
Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	1.	US-6,710,226-B1	03-23-2004	Schenk	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KAB	2.	WO-92/09699-A1	06-11-1992	L. F. Will & Cie S.A.	Translation of Abstract Only	
KAB	3.	WO-03/77858-A2, A3	09-25-2003	Neuralab Limited et al.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KAB	4.	International Search Report mailed May 11, 2006, for PCT Application No. PCT/US2005/027295 filed August 1, 2005, six pages.	
KAB	5.	Johnson-Wood, K. et al. (February 1997). "Amyloid Precursor Protein Processing and $A\beta_{42}$ Deposition in a Transgenic Mouse Model of Alzheimer's Disease," *PNAS USA* 94:1550-1555.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Ballard/	Date Considered	01/29/2007

pa-1093230

JAN 24 2007
PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	K. Ballard
Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	1.	US-2006/0292152-A1	12-28-2006	Rosenthal et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KAB	2.	WO-2006/118959-A2	11-09-2006	Rinat Neuroscience Corp.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KAB	3.	Asami-Odaka, A. et al. (2005). "Passive Immunization of the Aβ42(43) C-Terminal-Specific Antibody BC05 in a Mouse Model of Alzheimer's Disease," *Neurodegenerative Dis.* 2:36-43.	
	4.	Comery, T.A. et al. (2005). "Passive Immunization Against β-Amyloid Leads to Acute Cognition Improvement," *Society for Neuroscience*, Program No. 134.5, 2005 Abstract Viewer/Intinerary Planner, Abstract, one page.	
	5.	Donofrio, G. et al. (July 2005). "Paracrine Inhibition of Prion Propagation by Anti-PrP Single-Chain Fv Miniantibodies," *J. Virol.* 79(13):8330-8338.	
	6.	Ferrer, I. et al. (January 2004). "Neuropathology and Pathogenesis of Encephalitis Following Amyloid-β Immunization in Alzheimer's Disease," *Brain Pathol.* 14(1):11-20.	
	7.	Gelman, B.B. et al. (2004). "Brain Aging in Acquired Immunodeficiency Syndrome: Increased Ubiquitin-Protein Conjugate is Correlated with Decreased Synaptic Protein but not Amyloid Plaque Accumulation," *J. NeuroVirol.* 10(2):98-108.	
	8.	Green, D.A. et al. (March 2005). "Brain Deposition of Beta-Amyloid is a Common Pathologic Feature in HIV Positive Patients," *AIDS* 19(4):407-411.	
	9.	Jin, K. et al. (2004). "Familial Leptomeningeal Amyloidosis with a Transthyretin Variant Asp18Gly Representing Repeated Subarachnoid Haemorrhages with Superficial Siderosis," *J. Neurol. Neurosurg. Psychiatry* 75(10):1463-1466.	
	10.	Levites, Y. et al. (January 2006). "Anti-AB_{42}- and Anti-AB_{40}-Specific mAbs Attenuate Amyloid Deposition in an Alzheimer Disease Mouse Model," *The Journal of Clinical Investigation* 116(1):193-201.	
	11.	Lossos, A. et al. (March 2005). "Extended Phenotype in the Transthyretin Tyr77 Familial Amyloid Polyneuropathy," *Eur. Neurol.* 53(2):55-59.	
	12.	Mohajeri, M.H. et al. (2004). "Assessment of the Bioactivity of Antibodies Against β-Amyloid Peptide in vitro and in vivo," *Neurodegenerative Dis.* 1:160-167.	
KAB	13.	Nilsson, M. et al. (June 4, 2004). "Prevention of Domain Swapping Inhibits Dimerization and	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	K. Ballard
Sheet	2	of	2	Attorney Docket Number	514712001500

		Amyloid Fibril Formation of Cystatin C," *J. Biol. Chem.* 279(23):24236-24245.	
KAB	14.	Omidfar, K. et al. (2004). "Production of a Novel Camel Single-Domain Antibody Specific for the Type III Mutant EGFR," *Tumor Biology* 25:296-305.	
	15.	Racke, M.M. et al. (January 19, 2005). "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β," *J. Neurosci.* 25(3):629-636.	
	16.	Rebe, S. et al. (September/October 2005). "Deglycosylation of Anti-β Amyloid Antibodies Inhibits Microglia Activation in BV-2 Cellular Model," *American Journal of Alzheimer's Disease and Other Dementias* 20(5):303-313.	
KAB	17.	Tabatabai, G. et al. (March 2005). "Primary Amyloidoma of the Brain Parenchyma," *Arch. Neurol.* 62(3):477-480.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Ballard/	Date Considered	01/31/2007

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 1 of 8 1

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	~~S. Turner~~ K. Ballard
Attorney Docket Number	514712001500

KAB	37.	WO-00/77178-A1	12-21-2000	Boston Biomedical Research Institute			
	38.	WO-01/10900-A2, A3	02-15-2001	University of Southern California et al.			
	39.	WO-03/000714-A2, A3	01-03-2003	Panacea Pharmaceuticals, Inc.			
	40.	WO-03/015691-A2, A3	02-27-2003	Eli Lilly and Company			
	41.	WO-03/016467-A2, A3	02-27-2003	Eli Lilly and Company			
	42.	WO-03/039467-A2, A3	05-15-2003	Diagenics International Corporation			
	43.	WO-03/051374-A2, A3	06-26-2003	New York State Office of Mental Health			
	44.	WO-03/074081-A1	09-12-2003	Mindset Biopharmaceuticals USA Inc.			
	45.	WO-03/090772-A1	11-06-2003	Eli Lilly and Company			
	46.	WO-03/104437-A2, A3	12-18-2003	Northwestern University et al.			
	47.	WO-2004/001426-A2, A3	12-31-2003	Axonyx, Inc.			
	48.	WO-2004/024090-A2	03-25-2004	The Regents of the University of California			
	49.	WO-2004/024770-A1	03-25-2004	Universidad de Zaragoza			√
	50.	WO-2004/029630-A1	04-08-2004	Janssen Pharmaceutica N.V.			
	51.	WO-2004/032868-A2	04-22-2004	Rinat Neuroscience Corp.			
	52.	WO-2004/056318-A2	07-08-2004	New York University			
	53.	WO-2004/067561-A1	08-12-2004	Abbott GMBH & Co. KG	Translation of Abstract Only		
	54.	WO-2004/076677-A2, A3	09-10-2004	Institute for Research in Biomedicine			
	55.	WO-2004/098631-A1	11-18-2004	Universidad de Zaragoza			√
	56.	WO-2005/011599-A2	02-10-2005	Northwestern University			
	57.	WO-2005/018424-A2	03-03-2005	Research Foundation for Mental Hygiene, Inc.			
	58.	WO-2005/025516-A2	03-24-2005	The Regents of the University of California			
	59.	WO-2005/025616-A1	03-24-2005	Takeda Pharmaceutical Company Limited			√
	60.	WO-2005/028611-A2	03-31-2005	Centocor, Inc.			

Duplicates. Do not print.

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	61.	Akiyama, H. et al. (February 2004). "Specificity of Mechanisms for Plaque Removal after Aβ Immunotherapy for Alzheimer Disease," *Nature Medicine* 10(2):117-119.	
	62.	Bard, F. et al. (February 16, 2003). "Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection Against Alzheimer's Disease-Like Neuropathology," *Proc. Natl. Acad. Sci. USA* 100(4):2023-2028.	

Duplicates. Do not print.

Examiner Signature	K. Ballard	Date Considered	1/31/07

pa-996225

OIPE IAP72 MAY 08 2006 PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	K. Ballard
Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2003/0147887-A1	08-07-2003	Wang et al.	
	2.	US-2003/0165496-A1	09-04-2003	Basi et al.	
	3.	US-2004/0038302-A1	02-26-2004	Nitsch et al.	
	4.	US-2004/0087777-A1	05-06-2004	Basi et al.	
	5.	US-2005/0130233-A1	06-16-2005	Nitsch et al.	
	6.	US-2005/0239169-A1	10-27-2005	Nitsch et al.	
	7.	US-2006/0057701-A1	03-16-2006	Rosenthal et al.	
	8.	US-2006/0057702-A1	03-16-2006	Rosenthal et al.	
	9.	US-5,225,539-A	07-06-1993	Winter	
	10.	US-5,545,566-A	08-13-1996	Growden et al.	
	11.	US-5,631,168-A	05-20-1997	Growdon et al.	
	12.	US-5,677,425-A	10-14-1997	Bodmer et al.	
	13.	US-5,962,463-A	10-05-1999	Nitsch et al.	
	14.	US-6,329,155-B1	12-11-2001	Nitsch et al.	
	15.	US-6,548,640-B1	04-15-2003	Winter	
	16.	US-6,573,276-B2	06-03-2003	Hock et al.	

Duplicates. Do not print.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	17.	WO-02/20379-A1	11-26-1992	Repligen Corporation		*
KAB	18.	WO-02/25279-A2, A3	03-28-2002	Evotec Neurosciences GMBH et al.		
KAB	19.	WO-03/086310-A2, A3	10-23-2003	Ramot at Tel Aviv University Ltd.		
KAB	20.	WO-2004/058184-A2	07-15-2004	Rinat Neuroscience Corp.		
KAB	21.	WO-2004/095031-A1	11-04-2004	Universität Zürich		
	22.	WO-2006/030291-A2	04-06-2006	Rinat Neuroscience Corp.		*

Duplicates. Do not print.

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KAB	23.	Armour, K.L. et al. (2003) "Differential Binding to Human FcγRIIa and FcγRIIb Receptors by Human IgG Wildtype and Mutant Antibodies," *Molecular Immunology* 40:585-593.	
KAB	24.	Bach, J-F. et al. (1985). "Monoclonal Antibodies as Therapeutic Tools in Medicine" Chapter 22 *In* Handbook of Monoclonal Antibodies: Applications in Biology and Medicine, Ferrone, S. et al. eds., Noges Publications: Park Ridge: NJ, pp. 419-435.	

Examiner Signature	K Ballard	Date Considered	1/31/07